Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3)
Fabio Girardi, M Matz, Charles Stiller, Hui You, Rafael Marcos Gragera, М. Yu. Valkov, Jean‐Luc Bulliard, Prithwish De, David Morrison, Miriam Wanner, David O’Brian, Nathalie Saint‐Jacques, Michel P. Coleman, Claudia Allemani, CONCORD Working Group, S. Bouzbid, M Hamdi-Chérif, L Kara, Kaouel Meguenni, D. Regagba, Saray Mormeneo Bayo, T Cheick Bougadari, S S Manraj, Karima Bendahhou, A Ladipo, Olufemi J. Ogunbiyi, Nontuthuzelo Somdyala, M A Chaplin, Florencia Moreno, G.H. Calabrano, S.B. Espinola, B Carballo Quintero, R Fita, W.D. Laspada, S.G. Ibañez, Carlos Anselmo Lima, Allini Mafra da Costa, P.C.F. De Souza, J. Chaves, C. Laporte, María Paula Curado, J.C. de Oliveira, C.L.A. Veneziano, Donaldo Botelho Veneziano, Ana Beatriz Almeida, M R D O Latorre, Marise Souto Rebelo, M O Santos, G Azevedo e Silva, J.C. Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D.A. Herrmann, S Torres Vargas, Víctor Herrera, Claudia Uribe, Luis Eduardo Bravo, Luz Stella García, Nelson Enrique Arias-Ortiz, D Morantes, Daniel Jurado, María Clara Yépez Chamorro, Sandra Delgado, Melissa Ramirez, Y H Galán Alvarez, Priscila Torres, F Martínez-Reyes, L. Jaramillo, R. Quinto, J Castillo, M Mendoza, Patricia Cueva, J.G. Yépez, Bernard Bhakkan, Jacqueline Deloumeaux, Clarisse Joachim, Jonathan Macni, R Carrillo, J Shalkow Klincovstein, Rebeca Rivera-Gómez, P Pérez, Ebert Poquioma, Guillermo Tortolero‐Luna, Diego Zavala, R. Alonso, Enrique Barrios, Angela Eckstrand, C Nikiforuk, Ryan Woods, Glen Noonan, Donna Turner, Eshwar Kumar, B Zhang, Jeff Dowden, Gregory P. Doyle, Nathalie Saint‐Jacques, Gordon Walsh, A Anam, P De, Carol McClure
Abstract
BACKGROUND: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS: We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS: The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.